Investors & Media
Press Releases
2023
-
- October 19, 2023
-
Anokion to Participate in BofA Healthcare Trailblazers Conference
Read More
-
- October 12, 2023
-
Anokion Announces Upcoming Oral Presentation of Phase 1 Clinical Data with KAN-101 for Celiac Disease During United European Gastroenterology Week
Read More
-
- September 19, 2023
-
Anokion Announces Nature Biomedical Engineering Publication Further Validating its Immune Tolerance Approach to Treating Celiac Disease and Multiple Sclerosis
Read More
-
- September 12, 2023
-
Anokion Announces Clinical Progress with KAN-101 and ANK-700
Read More
-
- September 07, 2023
-
Anokion Strengthens its Senior Leadership with Promotions and New Appointment
Read More
-
- June 15, 2023
-
Anokion Announces Publication in The Lancet Gastroenterology & Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial
Read More
-
- May 09, 2023
-
Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modifying Treatment for Celiac Disease
Read More